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1092Objectives: Identification of variables influencing surgical outcome in patients treated for pulmonary atresia
with ventricular septal defect and major aortopulmonary collateral arteries.
Methods: A total of 90 consecutive patients (median age, 12 months; range, 20 days to 35 years), who had pri-
marily undergone either 1-stage unifocalization (n ¼ 69) or palliation to promote native pulmonary arterial de-
velopment (n ¼ 21), were studied. Chromosome 22q11 deletion had occurred in 37% of the cases. Ventricular
septal defect closure was accomplished in 70 patients (78%), with a mean postoperative right/left ventricular
pressure ratio of 0.48  0.14.
Results: The rate of 14-year survival, freedom from conduit reintervention, and freedom from percutaneous in-
tervention on the pulmonary arteries was 75%, 46%, and 52%, respectively. At a median interval of 95 months
(range, 1.5-164 months), the right/left ventricular pressure ratio did not differ significantly from early postop-
eratively. Univariate analysis showed that an absence of confluent intrapericardial pulmonary arteries favorably
affected the postoperative right/left ventricular pressure ratio after ventricular septal defect closure (P ¼ .04).
Kaplan-Meier estimates showed age of 30 days or younger (P ¼ .0004) and weight of 3 kg or less
(P¼ .0004) at unifocalization and chromosome 22q11 deletion (P¼ .001) significantly affected survival. Chro-
mosome 22q11 deletion was significantly associated with mortality, even in the Cox regression model (hazard
ratio, 8.26; P ¼ .003). Finally, ventricular septal defect closure during single-stage and single/multiple-stage
procedures significantly correlated with both early (P ¼ .0013 and P< .00001, respectively) and overall
(P ¼ .013 and P ¼ .0007, respectively) survival.
Conclusions: The results of surgery were satisfactory and durable, despite the need for repeated percutaneous or
surgical reinterventions. The outcomes were negatively affected by neonatal age and low body weight and pos-
itively affected by simultaneous or staged ventricular septal defect closure. Finally, chromosome 22q11 deletion
remained an independent variable affecting survival. (J Thorac Cardiovasc Surg 2010;140:1092-103)Pulmonary atresia with ventricular septal defect and major
aortopulmonary collateral arteries (PA/VSD/MAPCAs) is
the extreme form of tetralogy of Fallot, with complete right
ventricular outflow tract obstruction and the pulmonary
blood flow supplied by a variable number of systemic ar-
teries, differing in size, course, and distribution. The native
pulmonary arteries can have several degrees of hypoplasia
or even be absent. MAPCAs occur in 25% of patients
with tetralogy of Fallot and pulmonary atresia.1,2 Up to
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The Journal of Thoracic and Cardiovascular Surwith chromosome 22q11 deletion,3,4 showing more
complex patterns of pulmonary vasculature and less
favorable arborization of the true pulmonary arteries.5,6
The single-stage unifocalization procedure has proved to
be a very promising treatment strategy, aimed at construct-
ing a single, all-inclusive and unobstructed pulmonary
circulation district, possibly kept at low pressure by con-
comitant 2-ventricle repair, at the earliest possible age.7-10
However, the use of MAPCAs for the surgical treatment of
the disease is highly controversial owing to their erratic
morphologic features, with the related surgical pitfalls,
and, more crucially, to their intrinsic nature of bronchial
arteries with a purportedly limited potential for growth.11-13
Since 1998, either 1-stage unifocalization procedures or
palliative right ventricular outflow tract reconstruction
(RVOTR) has been selectively applied at our institution, ac-
cording to the preoperative morphometric evaluation of the
pulmonary blood sources.4,14,15 In the present study, we
analyzed our 15-year experience with surgical treatment of
PA/VSD/MAPCAs, with a particular focus on the effect of
the unifocalization procedures on early and late outcomes.gery c November 2010
Abbreviations and Acronyms
MAPCAs ¼ major aortopulmonary collateral
arteries
PA ¼ pulmonary atresia
pRV/pLV ¼ right/left ventricular pressure ratio
RVOTR ¼ right ventricular outflow tract
reconstruction
RV-PA ¼ right ventricle-pulmonary artery
TNPAI ¼ total neopulmonary arterial index
VSD ¼ ventricular septal defect
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Study Design
The medical records, angiographic studies, surgical reports, discharge
summaries, and clinic follow-up reports of all consecutive patients with
PA/VSD/MAPCAs treated between January 1994 and September 2009
were retrospectively reviewed. The institutional scientific board of the hos-
pital approved the present study. The following data at surgery had been
collected: age, weight, treatment era, association with chromosome
22q11 deletion (using fluorescent in situ hybridization), total neopulmo-
nary arterial index (TNPAI), MAPCAversus native pulmonary artery dom-
inance, the presence of central pulmonary arteries (either single or
bilateral), the presence of confluent intrapericardial and/or intraparenchy-
mal pulmonary arteries, and the early postoperative right/left ventricular
pressure (pRV/pLV) ratio. The following follow-up data were collected:
conduit reinterventions (either percutaneous or surgical), percutaneous in-
terventions on the pulmonary arteries, and the late pRV/pLV ratio. A major
change in perioperative transfusional policy and antimicrobial prophylaxis
for patients with chromosome 22q11 deletion was introduced in 2001, in-
cluding routine administration of irradiated blood products and modified
prophylaxis with broad-spectrum antibiotics and an antifungal agent.16
All morphologic and morphometric preoperative data of the pulmonary
blood supply were obtained from the angiographic studies. The early post-
operative pRV/pLV ratio was recorded from either indwelling or transtho-
racic catheters, with the left ventricular pressure inferred from the systolic
systemic arterial pressure. The late postoperative pRV/pLV ratiowas calcu-
lated at cardiac catheterization in patients free from major conduit or pul-
monary arterial stenoses.
Management Protocol and Surgical Technique
At the beginning of the study period, the patients had been strictly se-
lected according to the preoperative morphometric and functional evalua-
tion of the pulmonary blood sources. ATNPAI of 150 mm2/m2 was elected
as the main cutoff parameter.4,14,15,17 Furthermore, the pulmonary arteries
were considered hypoplastic when the pulmonary arterial index was less
than 100 mm2/m2.
Themanagement protocol subsequently evolved into the current policy of
selecting patients for procedures promotingnative pulmonary arterial growth,
provided that preoperative evidence of confluent, fully arborizing (i.e., dom-
inant), yet hypoplastic, native pulmonary arterieswas demonstrated. In all re-
maining cases with abnormal arborization of the native pulmonary arteries
and/or dominantMAPCAs, 1-stage complete unifocalizationwas performed.
The surgical procedures to promote native pulmonary arterial growth
consisted of palliative RVOTR using either conduit interposition or outflow
patching and, more recently, central aortopulmonary shunts. One-stage
unifocalization was always performed through a midline sternotomy, by
merging the collaterals with the native pulmonary arteries, when present,
or with each other using long side-by-side anastomoses. This was followed
by patch-augmenting the neoconstructed pulmonary arterial confluenceThe Journal of Thoracic and Carusing either untreated autologous pericardium or cryopreserved pulmonary
homograft tissue.14 The decision of whether to close the VSD after unifoc-
alization was determined by the findings from an intraoperative pulmonary
flow study.4,14,15 Finally, the conduits used for the right ventricle-to-
pulmonary artery connection, in the setting of both palliative RVOTR
and 1-stage unifocalization, changed widely during the study period and
included cryopreserved homografts and different types of heterografts.
Statistical Analysis
The data are expressed as the mean  standard deviation or as the me-
dian and range for continuous variables and as the proportion for categor-
ical variables. The early postoperative and late follow-up pRV/pLV ratios
were compared using Student’s paired t test. The end points for univariate
and multivariate analysis were the suitability of 1-stage unifocalization (all
patients), the suitability of simultaneous VSD closure (all patients undergo-
ing either primary or staged unifocalization), the postoperative pRV/pLV
ratio (all patients eventually undergoing VSD closure), and survival (all pa-
tients). The continuous variables examined included age and weight at
treatment, which were dichotomized at a cutoff of 30 days and 3 kg, respec-
tively, to explore the effect of neonatal age and low body weight on the re-
sults of unifocalization. TNPAI was exclusively considered as a categorical
variable, with a cutoff of 150 mm2/m2 as the main parameter for patient se-
lection, especially in our preliminary experience.4,14,15 Other categorical
variables examined included the presence or absence of confluent
intrapericardial and/or intraparenchymal pulmonary arteries, the
presence or absence of central pulmonary arteries, the presence or
absence of chromosome 22q11 deletion, collateral versus pulmonary
dominant arteries, era before or after 2001 (according to the changes in
the perioperative transfusional policy and antimicrobial prophylaxis
introduced in 2001 for patients with chromosome 22q11 deletion16). Uni-
variate analysis was performed using the c2 test or Fisher’s exact test for
categorical variables. Continuous variables were analyzed using Student’s
t test or one-way analysis of variance. The variables with P .1 on univar-
iate analysis were entered into a multivariate analysis performed using lo-
gistic regression analysis. Kaplan-Meier estimates of survival and freedom
from reintervention were calculated, and the survival estimates were com-
pared using the log-rank test. A comparison of the survival estimates also
included patients with or without simultaneous VSD closure during single-
stage and/or multiple-stage procedures. Survival was also analyzed using
a multivariate Cox regression model. All tests were 2-sided. Stata, version
11, data analysis and statistical software (StataCorp LP, College Station,
Tex) was used for statistical analysis.RESULTS
Patient Characteristics
The 90 patients included in the present study represented
the overall MAPCA patient population encountered during
the study period. Of these 90 patients, 27 (30%) had been
treated before 2001 and 63 (70%) after 2001. The median
age and weight at the first treatment was 12 months (range,
20 days to 35 years) and 8.2 kg (range, 2.5 to 54 kg), respec-
tively. The median age and weight at unifocalization was 15
months (range, 20 days to 35 years) and 8.7 kg (range, 2.5 to
68 kg), respectively. Chromosome 22q11 deletion, searched
for in all patients, was present in 33 (37%).Preoperative Angiography
The morphometric and functional evaluation of the pul-
monary blood sources was performed before surgery by
the same investigator using angiography for each patient.diovascular Surgery c Volume 140, Number 5 1093
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calculations and data on the following pulmonary blood
supply characteristics: (1) collateral or pulmonary arterial
dominance, expressed as a pulmonary artery/collateral ar-
tery lung segment perfusion ratio of 1 or less; (2) the pres-
ence of confluent intrapericardial pulmonary arteries (ie, all
anatomic arrangements in which seagull-shaped central
pulmonary branches were detectable, irrespective of their
size or segmental distribution to the lungs; and (3) the pres-
ence of central pulmonary arteries, either single or bilateral
(i.e., pulmonary arterial confluence or a single pulmonary
artery perfusing the ipsilateral lung). In addition, the pres-
ence of confluent intraparenchymal pulmonary arteries
was evaluated. This included all anatomic conditions in
which the greatest proportion of the lung segments was pro-
vided by native pulmonary arteries (pulmonary artery/col-
lateral artery lung segment perfusion ratio>1), in which
a single pulmonary artery was present and was distributed
to the whole ipsilateral lung, or in which a single MAPCA
was responsible for perfusion of a whole lung, even in the
absence of intrapericardial pulmonary arteries. The charac-
teristics of the pulmonary blood supply are listed in Table 1.
Treatments and Outcomes
Of the 90 patients entering the study, 21 with dominant
confluent hypoplastic native pulmonary arteries underwent
first-stage palliative RVOTR with conduit interposition
(n ¼ 14), outflow patching (n ¼ 4), or percutaneous perfo-
ration and balloon dilation of the atretic pulmonary valve
(n ¼ 1) or a central aortopulmonary shunt (n ¼ 2). Of these
21 patients, 17 underwent unifocalization as a second-stage
procedure at a median interval of 20 months (range, 2-220
months) from palliation, with an intraoperative pulmonaryTABLE 1. Pulmonary blood supply characteristics of all treated
patients
Characteristic Patients (n) %
TNPAI
<150 mm2/m2 26 29
 150 mm2/m2 64 71
Dominant collateral or pulmonary arteries
Spa/Sca ratio<1 40 44
Spa/Sca ratio>1 50 56
Central pulmonary arteries
No 12 13
Yes, single 20 22
Yes, bilaterally 58 65
Confluent intrapericardial pulmonary arteries
No 28 31
Yes 62 69
Confluent intraparenchymal pulmonary arteries
No 28 31
Yes 62 69
TNPAI, Total neopulmonary arterial index, Spa/Sca, pulmonary artery/collateral
artery lung segment perfusion.
1094 The Journal of Thoracic and Cardiovascular Surflow study and simultaneous VSD closure in 15. No deaths
occurred during the staging interval. All 69 initial patients
with abnormal pulmonary arterial arborization (n ¼ 29) or
either dominant (n ¼ 28) or exclusive (n ¼ 12) MAPCAs
underwent one-stage unifocalization, with a pulmonary
flow study in 56. Simultaneous VSD closure was accom-
plished in 44 patients. Early death (30 days) after unifoc-
alization occurred in 7 patients, 6 patients with the VSD left
open and 1 with the VSD closed. The 7 patients died of
cardiac failure (n ¼ 2) or chest (n ¼ 2) or airway (n ¼ 3)
bleeding. Of these 7 patients, 5 had a chromosome 22q11
deletion, 3 of whom, with the VSD left open, died of airway
bleeding. An additional 5 patients, all with DiGeorge syn-
drome, died late after the initial unifocalization. The deaths
were from airway bleeding in 1 patient with the VSD left
open at 1.5 months postoperatively, cardiac failure in 1 pa-
tient with a closed VSD at 12 months postoperatively, and
infection in 3 patients with a closed VSD. The infections
were respiratory syncytial virus in 1 patient (death at 2
months postoperatively) and fungal infection in 2 patients
(death at 2 and 2.5 months postoperatively). The remaining
78 patients were followed up for a median interval of 46
months (range, 1.5-165 months). For 8 patients who had
traveled from abroad for treatment, the follow-up data
were incomplete because of insufficient data retrieval after
their return to their original country. Of the patients who had
undergone a first-stage palliative procedure to promote pul-
monary arterial growth, 2 (no chromosome 22q11 deletion)
died late in the follow-up period (24 and 134 months after
repair), of cardiac failure after redo surgery. The remaining
6 were awaiting treatment completion after either a first-
stage (n ¼ 4) or a second-stage (n ¼ 2) procedure. Of those
who had had the VSD left open at the initial one-stage uni-
focalization, 11 underwent delayedVSD closure at amedian
interval of 25 months (range, 1-36 months) after unifocali-
zation. Of these 11 patients, 1, with DiGeorge syndrome,
died of airway bleeding at delayed VSD closure performed
30 months after the initial unifocalization. Finally, 7 pa-
tients were awaiting treatment completion at last follow-
up. The data on surgical treatment are summarized in
Figure 1 and Table 2. Survival is depicted in Figure 2, A.
Of the 56 survivors with a closed VSD, for whom the
follow-up data were complete, 55 were asymptomatic and
1 with a hypertensive right ventricle had congestive heart
failure. The oldest patient of the series who had undergone
1-stage unifocalization and repair at 35 years old had a un-
eventful pregnancy and delivered a normal child through
cesarean section at 32 months postoperatively.
Reintervention
During the follow-up period, 25 patients underwent con-
duit reinterventions, including percutaneous conduit balloon
dilatation in 1, surgical replacement in 17, percutaneous con-
duit balloon dilatation followed by surgical replacement in 3,gery c November 2010
FIGURE 1. Management protocol for patients with pulmonary atresia, ventricular septal defect, and major aortopulmonary collateral arteries (PA/VSD/
MAPCAs). n, Number of patients for each group; P.Art., pulmonary arterial;MAPCAs, major aortopulmonary collateral arteries; RVOTR, right ventricular
outflow tract reconstruction; VSD, ventricular septal defect.
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ody valve (Medtronic,Minneapolis,Minn) insertion in 1, and
surgical replacement followed by percutaneous stented Mel-
ody valve insertion in 1. The rate of freedom from conduit re-
interventions was 91% at 1 year, 75% at 2 years, 71% at 5
years, 55% at 10 years, and 46% at 14 years (Figure 2, B).
Percutaneous interventions on the pulmonary arteries were
performed in 30 patients, once in 20 (dilatation in 18 and
stenting in 2 patients) and 2 or more times in 10 (dilatation
in 9 and stenting in 1 patient). The rate of freedom from
percutaneous interventions on the pulmonary arteries was
80% at 1 year, 65% at 2 years, 54% at 5 years, and 52% at
10 and 14 years (Figure 2, C).TABLE 2. Surgical data for 90 patients with pulmonary atresia,
ventricular septal defect, andmajor aortopulmonary collateral arteries
Variable Patients (n) %
Staging to promote native pulmonary
arterial growth
21 23
Unifocalization 86 95
Single-stage procedure 69 80
Second-stage procedure 17 20
VSD management at unifocalization
Intraoperative pulmonary flow study 71 82
VSD closed 59 69
VSD left open 27 31
Delayed VSD closure 11 41
Complete repair 70 78
Postoperative early pRV/pLV ratio
after repair
All patients 70 0.48  0.14
Patients entered in paired t test analysis 35 0.51  0.14
VSD, ventricular septal defect; pRV/pLV, right/left ventricular pressure.
The Journal of Thoracic and CarIn 35 repaired patients undergoing late cardiac catheter-
ization at a median interval from repair of 95 months (range,
1.5-164 months), the mean postoperative pRV/pLV ratio
was 0.53  0.18.Statistical Analysis
The comparison between the early postoperative period
and late follow-up showed that the pRV/pLV ratio did not
change significantly (P ¼ .579).
An analysis of the end points showed the following
results.
Suitability of 1-stage unifocalization. The suitability of
1-stage unifocalization is also discussed in Appendix 1.
Univariate analysis of 90 observations showed that only
a TNPAI of 150 mm2/m2 or greater was significantly asso-
ciated with the suitability of 1-stage unifocalization
(P ¼ .006). No other categorical or continuous variables
reached the cutoff value to be entered in the multivariate
analysis.
Suitability of simultaneous VSD closure. The suitability
of simultaneous VSD closure is also discussed in Appendix
2. On univariate analysis of 86 observations, the later era
(2001-2009) was significantly associated with a decreased
suitability of concomitant VSD closure (P ¼ 0.027). That
variable qualified for entry in the multivariate analysis, to-
gether with chromosome 22q11 deletion (P ¼ .098 on uni-
variate analysis) and remained significant on multivariate
analysis (odds ratio, 0.35; P ¼ .025). Chromosome 22q11
deletion approached, but did not reach, significance on mul-
tivariate analysis (odds ratio, 0.399; P ¼ .064).
Postoperative pRV/pLV ratio. The postoperative pRV/
pLV ratio is also discussed in Appendix 3. Univariatediovascular Surgery c Volume 140, Number 5 1095
FIGURE 2. Kaplan-Meier estimates. A, Survival of all patients treated. B, Freedom from conduit reintervention for 78 patients who entered follow-up. C,
Freedom from percutaneous interventions on pulmonary arteries for 78 patients who entered follow-up. CI, Confidence interval; PAs, pulmonary arteries.
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FIGURE 3. Kaplan-Meier estimates. A, All patients treated according to age at unifocalization stratified by cutoff of 30 days of age. B, All patients treated
according toweight at unifocalization stratified by cutoff of 3 kg. C, All patients treated according to association with chromosome 22q11 deletion (del 22q).
D, All patients undergoing 1-stage unifocalization stratified by simultaneous closure of ventricular septal defect (VSD).
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fluent intrapericardial pulmonary arteries favorably af-
fected the postoperative pRV/pLV ratio (P ¼ .04). No
other categorical or continuous variable reached the cutoff
value for entry into the multivariate analysis.
Survival. Univariate analysis of 90 observations showed
that age of 30 days or younger (P ¼ .0004) and weight of
3 kg or less (P ¼ .0004) at unifocalization and the presence
of chromosome 22q11 deletion (P ¼ .001) were significant
risk factors for mortality (Figure 3,A–C). Age and weight as
continuous variables and chromosome 22q11 deletion,
dominant collateral/pulmonary arteries, and era at treat-
ment as categorical variables were entered into a Cox re-
gression model, which showed that the presence of
chromosome 22q11 deletion was an independent variable
affecting survival (hazard ratio, 8.26; P ¼ .003). No other
variable examined exerted significant attrition on mortality
(see Appendix 4). Finally, a comparison of the survival
estimates for patients with or without simultaneous VSD
closure during single-stage and/or multiple-stage proce-
dures showed that VSD closure significantly correlatedThe Journal of Thoracic and Carwith both early (P ¼ .0013) and overall (P ¼ .013) survival
during single-stage procedures (Figure 3, D) and with both
early (P<.00001) and overall (P ¼ .0007) survival during
single- and multiple-stage procedures.
DISCUSSION
The management of PA/VSD/MAPCAs is quite contro-
versial. Differing opinions about the role of MAPCAs and
their reciprocal relationship with true pulmonary arteries
have led various groups to embrace totally opposite surgical
positions.7-13,18-21 The Melbourne group, which originally
pioneered the concept of unifocalization,20 has recently
abandoned it, recognizing the unsatisfactory long-term re-
sults of unifocalization in their historical series (ie, a 65%
repair rate with a 12-year survival rate of 51%  14% and
a pRV/pLV ratio of 0.62  0.32 at a median follow-up of
1.38 years). They attributed such results exclusively to the
growth of the native pulmonary circulation and speculated
that the unifocalized MAPCAs either thrombosed or failed
to grow.12 Therefore, they shifted to the sole use of native
pulmonary arteries, irrespective of their or their anddiovascular Surgery c Volume 140, Number 5 1097
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drastically changed their surgical outcomes. For 18 patients
treated during a 6-year period, the overall survival rate im-
proved to 94%, but the total repair rate was only 41%, and
the median postoperative pRV/pLV ratio was 0.59 at a me-
dian follow-upof 13months.13The collateralswere either ig-
nored or ligated. No cases of absent pulmonary arteries were
described, a situation that occurred in 13% of patients in our
series and in 23.5% at Stanford.10
Over the years, we have consolidated a tailored approach
to PA/VSD/MAPCAs using a systematic preoperative eval-
uation of pulmonary blood sources.4,14,15 Our 15-year
experience has revealed satisfactory and durable results,
with a total repair rate of 78%, overall 14-year survival
rate of 75%, and steadily favorable pRV/pLV ratio at
a median follow-up of 8 years. These data correlate with
those from the Stanford group, which introduced 1-stage
unifocalization and achieved complete repair in up to
90% of patients.10 Such polar opposite results compared
with the Melbourne experience12 might reflect the inherent
advantages of 1-stage midline unifocalization compared
with the traditional staged approach through multiple thora-
cotomies. Furthermore, the routine aggressive catheter rein-
terventions on the pulmonary arterial tree to stabilize the
results of unifocalization9,10,21 might have amplified such
differences compared with the conventional approach.
In the present study, actuarial analyses showed that the
conduit pathologic diseasewas progressive during the entire
follow-up interval. The 2 main declines in the freedom from
reintervention occurred at 2 and 5 to 10 years, respectively,
probably owing to the small size of heterografts for the for-
mer and average conduit duration for the latter. Such trends
might indicate the uneven conduit choice made at first im-
plantation, especially for the smaller sizes, owing to the lim-
ited availability of homografts. However, the freedom from
percutaneous interventions on the pulmonary arteries
showed the greatest decrease within the first 2 postoperative
years, suggesting that a substantial proportion of our pa-
tients took advantage of timely interventional procedures.
The early need for catheter-based reinterventions was also
reported by others.21,22 In our series, the long-term pRV/
pLV ratio did not differ substantially from the early postop-
erative ratio, probably reflecting a well-preserved pulmo-
nary arterial compliance after unifocalization.
Given that the late pRV/pLV ratio strictly reflects the
early postrepair hemodynamics in our and others’ experi-
ence,10 both the suitability of VSD closure at unifocaliza-
tion and the pRV/pLV ratio at repair become keystones of
treatment. In our series, a later era was significantly associ-
ated with a lower suitability of simultaneous VSD closure
on both univariate and multivariate analysis and chromo-
some 22q11 deletion approached, but did not reach, signif-
icance. We speculated that the attrition of the later era on
such an end point was fortuitous and possibly reflected1098 The Journal of Thoracic and Cardiovascular Surthe occurrence of more complex cases in our more recent
experience. However, the weak effect of chromosome
22q11 deletion on the suitability of simultaneous VSD clo-
sure (odds ratio, 0.399), although not strictly significant
(P ¼ .064), might have correlated with the complexity of
pulmonary vascular patterns described in such syndromic
associations.5,6 The analysis of the early pRV/pLV ratio
showed that the absence of confluent intrapericardial
pulmonary arteries was significantly associated with more
favorable postoperative hemodynamics. This, together
with the observation that early and late hemodynamics are
strictly related, outlines the crucial role of the collaterals
used for the reconstruction of neopulmonary arteries and
strongly substantiates the effectiveness of unifocalization
procedures.
On univariate analysis, a TNPAI of 150 mm2/m2 or
greater was significantly associated with the suitability for
1-stage unifocalization. This result was most probably bi-
ased by the use of TNPAI as a surgical indication during
our earlier experience.14,15 On the whole, however, the
TNPAI cutoff of 150 mm2/m2 failed to correlate with
feasibility of VSD closure during 1-stage unifocalization,
corroborating the general concern about the TNPAI as
a reliable predictor of the suitability of repair8,15,23 and
further outlining the key role of the intraoperative
pulmonary flow study.4,8,23
Neonatal age and low body weight (3 kg) at unifocali-
zation were significantly associated with mortality, and
chromosome 22q11 deletion was an independent variable
affecting survival, irrespective of the pulmonary blood sup-
ply characteristics or the era at treatment. The attrition of
age at surgery was also reported by others. d’Udekem and
colleagues12 reported older age at first operation as the
only significant, but weak, factor predictive of longer late
survival. Amark and colleagues22 reported earlier age at re-
pair as a risk factor for death after surgery. Davies and col-
leagues21 and Malhotra and Hanley10 suggested, although
without providing enough evidence, that a key determinant
of long-term success is maximal recruitment of the lung
segments at an early age. In our series, although on Cox re-
gression analysis, age as a continuous variable did not cor-
relate with mortality, the dichotomized analysis showed the
neonatal period and a low body weight to be significantly
related to increased mortality at unifocalization. These ob-
servations support our current policy to avoid unifocaliza-
tion procedures before the stabilization of the pulmonary
vascular resistance. Our preferred approach for unifocaliza-
tion now involves patients weighing more than 5 kg, regard-
less of their age.
In the present analysis, Cox regression analysis showed
chromosome 22q11 deletion as a strong independent variable
affecting survival, confirming previous observations.4,24,25
The attrition effect of this syndrome was likely related to the
depressed immunologic status with ensuing susceptibility togery c November 2010
Carotti et al Congenital Heart Diseaseinfections and a propensity toward airway bleeding.16 In con-
trast, neither the complexity of the pulmonary vascular pat-
terns nor a later era at treatment exerted significant attrition
on survival, suggesting that themajor changes in perioperative
policy,16 adopted since 2001, presumably reduced periopera-
tivemorbidity, without significantlymodifying the survival of
patients with 22q11 deletion.
Finally, an analysis of survival estimates showed a signif-
icant correlation between VSD closure and both early and
overall survival with either single- or multiple-stage proce-
dures. Similarly, Davies and colleagues21 demonstrated
a protective effect of VSD closure without a significant sur-
vival advantage of single-stage versus multiple-stage VSD
closure. These data completely diverge from those from
the Melbourne analysis, in which no significant difference
in long-term follow-up was seen between the repaired and
palliated patients,12 further highlighting the striking differ-
ence between the 2 approaches.C
H
DStudy Limitations
This was a single-center, retrospective study in which
a protocol of treatment was analyzed in the absence of a con-
trol group. The follow-up data were incomplete for 8 (10%)
of 78 patients owing to insufficient data retrieval from for-
eign countries. Some results of the analysis might have been
biased by the use of some parameters (e.g., TNPAI) as se-
lection criteria. The crucial role of unifocalization within
our protocol of treatment might have led to the overestima-
tion of the more favorable postoperative hemodynamics
after VSD closure in patients without confluent intrapericar-
dial pulmonary arteries.CONCLUSIONS
The surgical results from a protocol of primary or staged
(ie, after RVOTR) unifocalization in patients with PA/
VSD/MAPCAs were satisfactory and durable, despite the
need for repeated percutaneous or surgical interventions on
the pulmonary arteries or conduits. The use of systemic col-
lateral arteries for neopulmonary arterial reconstruction en-
sures totally functional pulmonary blood flow, compensates
for defects in true pulmonary arterial distribution, and is the
only option for patients with absent pulmonary arteries.
Avoiding neonatal age and low body weight might im-
prove survival at unifocalization, as would VSD closure, ei-
ther primary or staged. The presence of intrapericardial
pulmonary arteries did not improve the hemodynamic result
after VSD closure. Finally, chromosome 22q11 deletion re-
mained an independent variable affecting survival.References
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DrFrankL.Hanley (Stanford, Calif).Congratulations, DrCarotti,
for a very nice presentation and congratulations to you and your
colleagues for an outstanding series.
Consensus regarding the management and outcomes of patients
with pulmonary atresia and collaterals has been hard to come by.
This study fromBambinoGesu´ Children’s Hospital adds to a grow-
ing international experience that is allowing some consensus to fi-
nally emerge. This study, along with other notable large series with
careful midterm follow-up, such as the 500-or-so plus cases from
the Stanford group and the roughly 300-or-so from the Birming-
ham, England, group, to name just a few, now provide an interna-
tional multiple center experience that is approaching 1000 cases or
more and provide a fairly clear picture regarding some very impor-
tant points with respect to this lesion.
The 3 major conclusions that I think we now pretty much have
a consensus on are the following:
First, when unifocalization is performed aggressively and rela-
tively early in life according to strict protocols coupled with intra-
cardiac repair, midterm outcomes can be achieved that improve
quite dramatically on the natural history of the disease.
Now, that might not sound like much of a comment. However, it
is notable that as recently as 5 to 10 years ago, and even up to this
present day, the question of whether surgery improves on the nat-
ural outcome has been seriously debated. Now, there is absolutely
no question that surgery improves the outcome.
I would go one step further and say that protocols such as yours,
which is very close to our protocol and quite close to, I think, Dr
Brawn’s protocol, also provide probably the best outcomes relative
to other alternative, competing surgical procedures.
The second point that I think we have a consensus on is that col-
lateral arteries when unifocalized correctly contribute importantly,
even critically, to a durable, growing, healthy pulmonary vascular
bed. Your excellent outcomes in this series with patients with com-
pletely absent native pulmonary arteries, that is, those patients
whose pulmonary vascular bed was reconstructed solely from
the collateral arteries, reflects our own program’s experience pretty
much exactly and underscores this point, that collaterals clearly
are very important.
The third major point is the following: ‘‘Tending the garden,’’ if
you will, that is, frequent assessment of, and surgery and catheter-
based management of, the reconstructed pulmonary vascular bed
are all extremely necessary parts of the long-term treatment of
these patients. Again, I think there is a growing consensus about
that.1100 The Journal of Thoracic and Cardiovascular SurThese points of consensus notwithstanding, many differences
remain in individual institutions with respect to the specifics of
the management protocols and the identification of the various
risk factors. Also, clearly, we cannot go into all of those nuances
and variations in this short period. I do want to focus on one area.
Your outcomes are outstanding. If you eliminated the one sub-
group, the mortality in the one subgroup (i.e., thosewho had under-
gone complete unifocalization and failed the flow study and did
not have VSD closure), if you eliminated the mortality, or equaled
the mortality, in that subgroup as in all your other subgroups, your
outcomes would be phenomenal. So that is where I want to focus.
I notice that you identified VSD closure as a risk factor for mor-
tality. In the 25 patients in that subgroup, complete unifocalization
without VSD closure, 6 patients died. I was wondering whether
you could say a few things about your insights into that subgroup
and specifically address the following questions:
When you do the flow study, what criteria for the flow study do
you use specifically to make that decision? Because that might af-
fect on why some of them were not doing well.
Second, and, perhaps, even more importantly, in this answer to
this question, how do you provide the pulmonary blood flow, be-
cause you were not closing the VSD? Do you use a shunt? Do
you use some form of right ventricle-pulmonary artery (RV-PA)
connection? Do you put a VSD patch on and then fenestrate it?
What are your thoughts on that?
Dr Carotti. Thank you very much for your comment and for
your questions.
Regarding the pulmonary flow study, we perform it exactly as
we learned from you in 1996 when we visited your center. We use
a derivation from the arterial port of the oxygenator to perfuse the
pulmonary vascular tree with oxygenated blood. We cool down
the patient to a nasopharyngeal temperature of 25C. We keep the
hematocrit at 25%. Then, with the heart beating, we perfuse
the pulmonary arterial tree by incremental steps up to 100%
of the cardiac index and record simultaneously the mean pulmo-
nary arterial pressure changes. We rely on a cutoff value of
30 mm Hg and decide to close the VSD as long as the mean
pulmonary arterial pressure remains within such a value. For
any pressure value exceeding 30 mm Hg, we leave the VSD un-
touched and provide pulmonary blood flow using a RV-PA con-
duit with the VSD left open. In a couple of patients with the
VSD left open, we banded the conduit because of a progressive
increase in the arterial oxygen saturation, to avoid overperfusion
of the pulmonary arterial bed.
We never perform primary closure of the VSD using a fenes-
trated patch. However, in our early experience, we had 2 patients
who developed hypersystemic right ventricular pressure after
VSD closure despite falsely reassuring pulmonary flow study find-
ings. In both cases, we decided to fenestrate the patch, and those
were the only patients who ended up with a fenestrated VSD patch
closure.
Regarding the use of a systemic pulmonary shunt, we did it once
in our very early experience by replacing the conduit originally im-
planted. However, that patient died. At the postmortem, she had
diffuse pulmonary vascular disease. She was a 12-year-old child.
After this unsuccessful experience, we have always preferred to
perform right ventricular outflow tract reconstruction to provide
blood flow to the lungs.gery c November 2010
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from your answer, that you do pretty much a standard flow study
with well-recognized parameters for deciding when to close
a VSD.
Just for the sake of argument, we, in our program, we never
open the right ventricle unless we are going to close the VSD.
Thus, everybody who fails a flow study receives a well-controlled
shunt, in an attempt to achieve a mean pressure of 25 mmHg in the
pulmonary arteries.
Now, I do not know whether that enters into why you had a 6 of
25 patient mortality. Not that that is terrible. I mean your results
overall are outstanding. But this is a sort of the hot spot where
you had a few little problems. We originally used RV-PA conduits
early in the game. By 2000, we had switched completely to shunts
when the flow study failed because we were having complications
with the systemic level RV-PA conduits and the ability to really
control the blood flow in the lungs really well.
Again, when creating a ventriculotomy, pulmonary insufficiency
is going to be present chronically and also pseudoaneurysms, et ce-
tera. All those thingswe found to be concerns. I do not knowwhether
the shunt makes the difference. It is a relatively small number and it
might not, but I am just pointing out some differences.
Dr Carotti. To corroborate what you say, in our experience,
a few patients with the VSD left open died because of massive pul-
monary hemorrhage, likely secondary to uncontrolled pulmonary
blood flow. In our mind, the most appealing reason to have an
RV-PA conduit providing forward flow is the optimal access for
percutaneous interventions, which might enhance the perspectives
of subsequent VSD closure. Actually, most of our patients who ex-
perienced massive pulmonary hemorrhage had chromosome
22q11 deletion, which remains an important risk factor for death
in our analysis, and we were more keen to correlate the airway
bleeding to the syndrome itself than to the uncontrolled pulmonary
blood flow. Anyway, I take your suggestion.
DrHanley. Then, a second very brief question. I noticed in your
manuscript, and I think in the presentation as well, the mean age at
which you performed unifocalization was 15 months. Now, I know
very well, as you do, when you are getting referrals, you cannot
control the patient’s age all the time. I also wonder whether that
slightly older age might have had something to do with some ofThe Journal of Thoracic and Carthose patients who had variable pulmonary blood flow with per-
haps slightly sick pulmonary microvascular systems because of
the long-term flow, up to 15 months. Again, the analogy I usually
make is you would never let a truncus go 15 months before you
would repair it. You know the patients are going to have pulmonary
vascular problems. I know you cannot control the age. Left in the
ideal situation, if you were referred a newborn, when would you
perform the unifocalization?
Dr Carotti. When the body weight is 5 kg.
Dr Sabine Daebritz (Duisburg, Germany). Thank you for this
very interesting talk.
Can you briefly comment on the criteria you used to decide
when to close the VSD once you had left it open.
Dr Carotti. Yes. Thank you first for your question.
We do rely only on the intraoperative pulmonary flow study and
on a mean pulmonary arterial pressure cutoff value of 30 mm Hg.
If we reach up to 30 mmHg for the mean pulmonary arterial blood
pressure during flow study, we go ahead and close the VSD. Other-
wise we leave the VSD open.
Dr Tweddell. I think she is asking, in those patients, when you
leave it open, when do you subsequently go back and close it?
Dr Carotti. I am sorry, I did not understand.
Usually, we restudy those patients about 12 months after the op-
eration and see what the pulmonary blood flow/systemic blood
flow (Qp/Qs) ratio is. In the absence of significant stenosis at the
distal anastomosis of the conduit, or at the unifocalization site,
we accept a Qp/Qs ratio greater than 1.5:1 to proceed with VSD
closure. Otherwise, we could accept an even lower Qp/Qs ratio
in the presence of significant stenoses, which would be treated at
operation.
What we learned from our most recent experience is that those
patients react during catheterization also to hyperoxia and nitrous
oxide administration. In the last couple of patients with a basic Qp/
Qs ratio of 1:1, hyperoxia increased the Qp/Qs ratio to 2:1 and ni-
trous oxide to 2.5:1. So we are also doing vasoreactivity functional
tests when we restudy such patients.
Dr Tweddell. When you do the flow study, what index do you
target?
Dr Carotti. 2.5 L/min/m2.
Dr Tweddell. Thank you very much.diovascular Surgery c Volume 140, Number 5 1101
APPENDIX 1. Univariate model fit for suitability for one-stage
unifocalization (categorical)
Variable
Obs
(n ¼ 90)
No
(n ¼ 4)
Yes
(n ¼ 86)
P
value
Age (days) 1.000
30 3 0 3
>30 87 4 83
Weight (kg) 1.000
3 3 0 3
>3 87 4 83
TNPAI (mm2/m2) .006
<150 26 4 22
150 64 0 64
Confluent intrapericardial
pulmonary arteries
.306
No 28 0 28
Yes 62 4 58
Confluent intraparenchymal
pulmonary arteries
.306
No 28 0 28
Yes 62 4 58
Central pulmonary arteries .758
No 12 0 12
Yes, single 20 0 20
Yes, bilateral 58 4 54
Chromosome 22q11 deletion .292
No 57 4 53
Yes 33 0 33
Dominant collateral or
pulmonary arteries
.126
MAPCAs 40 0 40
PAs 50 4 46
Era at treatment .312
1994–2000 27 0 27
2001–2009 63 4 59
Univariate model fit for suitability for one-stage unifocalization
(continuous)
Variable Obs Mean 95% CI P value
Age .30
No 4 9 6.9-24.9
Yes 86 44.1 29.7-58.3
Weight .24
No 4 5.9 2.1-9.8
Yes 86 13.7 10.9-16.5
n, Number of patients for each group; Obs, observations; TNPAI, total neopulmonary
arterial index; MAPCAs, major aortopulmonary collateral arteries; PAs, pulmonary
arteries; CI, confidence interval.
APPENDIX 2. Univariate model fit for suitability for simultaneous
VSD closure (categorical)
Variable
Obs
(n ¼ 86)
No
(n ¼ 27)
Yes
(n ¼ 59) P value
Age (days) .231
30 3 2 1
>30 83 25 58
Weight (kg) .231
3 3 2 1
>3 83 25 58
TNPAI (mm2/m2) 1.000
<150 22 7 15
150 64 20 44
Confluent intrapericardial
pulmonary arteries
.623
No 28 10 17
Yes 58 18 41
Confluent intraparenchymal
pulmonary arteries
.623
No 28 10 17
Yes 58 18 41
Central pulmonary arteries .271
No 12 4 8
Yes, single 20 9 11
Yes, bilateral 54 14 40
Chromosome 22q11 deletion .098
No 53 13 40
Yes 33 14 19
Dominant collateral or
pulmonary arteries
.162
MAPCAs 40 16 24
PAs 46 11 35
Era at treatment .027
1994–2000 27 4 23
2001–2009 59 23 36
Univariate model fit for suitability for simultaneous VSD closure
(continuous)
Variable Obs Mean 95% CI P value
Age .40
No 27 35.7 13.8–57.7
Yes 59 47.8 29.2–66.5
Weight
No 27 12.1 7.5–16.7 .40
Yes 59 14.4 10.8–17.9
Logistic regression model fit for suitability for simultaneous VSD
closure
Variable Ref. Cat. Odds ratio (95% CI) P value
Chromosome 22q11
deletion
Yes 0.399 (0.150-1.056) .064
Era at treatment 2001–2009 0.249 (0.074-0.839) .025
n, Number of patients for each group; VSD, ventricular septal defect; Obs, observa-
tions; TNPAI, total neopulmonary arterial index; MAPCAs, major aortopulmonary
collateral arteries; PAs, pulmonary arteries; CI, confidence interval; Ref.Cat., refer-
ence category for each variable.
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APPENDIX 3. Univariate model fit for postoperative pRV/pLV ratio
Variable (Obs ¼ 70) Coef. 95% CI P value
Age
Categorical (30 vs>30 days) 0.08 0.37–0.20 .55
Continuous 0.00 0.00–0.00 .20
Weight
Categorical (3 vs>3 kg) 0.08 0.37–0.20 .55
Continuous 0.00 0.00–0.00 .39
TNPAI (<150 vs 150 mm2/m2) 0.02 0.09–0.06 .66
Confluent intrapericardial pulmonary
arteries (no [0] vs yes [1])
0.07 0.00–0.15 .04
Confluent intraparenchymal pulmonary
arteries (no vs yes)
0.03 0.10–0.04 .46
Central pulmonary arteries (no vs yes) 0.03 0.01–0.08 .18
Chromosome 22q11 deletion (no vs yes) 0.05 0.01–0.12 .14
Dominant collateral or pulmonary arteries
(MAPCAs vs PAs)
0.00 0.07–0.07 .97
Era at treatment (1994-2000 vs 2001-2009) 0.04 0.11–0.02 .22
n, Number of patients for each group; pRV/pLV, right/left ventricular pressure; Obs,
observations; Coef., coefficient; CI, confidence interval; TNPAI, total neopulmonary
arterial index; MAPCAs, major aortopulmonary collateral arteries; PAs, pulmonary
arteries.
APPENDIX 4. Cox regression model fit for mortality
Variable Ref.Cat. Hazard ratio (95% CI) P value
Age (continuous) 1.002 (0.986–1.019) .760
Weight (continuous) 1.029 (0.942–1.125) .519
Chromosome 22q11
deletion
Yes 8.260 (2.063–33.065) .003
Dominant collateral
or pulmonary arteries
MAPCAs 2.092 (0.672–6.512) .203
Era at treatment 2001–2009 1.044 (0.344–3.169) .939
Ref.Cat., Reference category for each variable; CI, confidence interval; MAPCAs,
major aortopulmonary collateral arteries.
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